CME Activities
Online Programs
Updates in Acute Myeloid Leukemia: What Are Best Practices for Personalizing Therapy for Patients Within the Department of Veterans Affairs?
PROGRAM CHAIR
Courtney D. DiNardo, MD, MSCE
Associate Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
PROGRAM OVERVIEW
In this enduring program, we will discuss how healthcare providers within the Department of Veterans Affairs can improve their treatment of patients with acute myeloid leukemia (AML) by providing updates on key biological features and biomarkers of AML to inform patient assessment with novel therapies. In addition, we will review the latest data on AML management and challenges in effectively communicating the rationale for therapeutic decisions with patients and caregivers.
TARGET AUDIENCE
This enduring activity is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with AML within the Department of Veterans Affairs.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Analyze current data concerning molecular and genetic markers to inform therapeutic decision-making in AML for patients within the Department of Veterans Affairs
- Understand the latest strategies for management of newly diagnosed and relapsed/refractory AML as informed by patient-specific features for patients within the Department of Veterans Affairs
- Evaluate current data concerning management of adverse events and implementation of shared decision-making to implement therapy in AML for patients within the Department of Veterans Affairs
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure of Relevant Financial Relationship(s)
| Speaker | Relationships | Manufacturer |
| Courtney D. DiNardo, MD | Consultant | AbbVie, Bristol Myers Squibb, Genmab, Gilead Pharmaceuticals, GlaxoSmithKline, ImmunoGen, Jazz Pharmaceuticals, Novartis, Rigel, and Servier Laboratories |
| Contracted Research | AbbVie, Astex, Bristol Myers Squibb, Cleave Therapeutics, Foghorn Therapuetics, Rigel Pharmaceuticals, Immune-Onc Therapeutica, Loxo Oncology, and Servier Laboratorie |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Sylvia Hanna, Medical Services for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager, has nothing to disclose.
- Emmanuella Foucault, Program Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITY ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the enduring activity at info@medlearninggroup.com
RELEASED DATE: August 02, 2023
EXPIRATION DATE: August 02, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Improving Approaches to Care for Patients with Acute Myeloid Leukemia: Insights from the Experts to Navigate an Evolving Landscape
PROGRAM CHAIR & FACULTY PRESENTER
Michael R. Grunwald, MD, FACP
Chief, Leukemia Division
Director, Transplantation and Cellular Therapy Program
Levine Cancer Institute, Atrium Health
Clinical Associate Professor, Wake Forest School of Medicine
Charlotte, NC
PROGRAM OVERVIEW
This enduring activity will explore the management of patients with newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) through didactic slide review, case study discussion, and a robust Q&A session. This program will address the role of genetic and molecular markers in treatment selection as well as best practices for treatment of newly diagnosed, relapsed/refractory, and secondary AML. A summary of approaches to treatment-related adverse event recognition and mitigation will also be discussed.
TARGET AUDIENCE
This educational activity is intended for U.S.-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with AML.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Appraise current data concerning molecular and genetic markers to inform therapeutic decision-making in AML
- Describe the latest strategies for management of newly diagnosed and relapsed/refractory AML as informed by patient-specific features
- Assess current data concerning management of adverse events and implementation of shared decision-making to implement therapy in AML
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Michael R. Grunwald, MD, FACP | Consulting fees: AbbVie, Amgen, Astellas, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, CTI BioPharma, Daiichi Sankyo, Genentech, Gilead Sciences, GSK/Sierra Oncology, Incyte, Invitae, Jazz, Novartis, Ono Pharmaceutical, Pfizer, Pharmacosmos, Premier, Servier/Agios, and Stemline Therapeutics. Research support: Incyte and Janssen. Stock ownership: Medtronic. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Tara Nelson-Mayfield, MS, Medical Director for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
- Laura Aibara, Program Coordinator, for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASED DATE: August 14, 2023
EXPIRATION DATE: August 14, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Approaches to Improving Care in Chronic Lymphocytic Leukemia Patients Within the Department of Veterans Affairs: Insights from the Experts
PROGRAM CHAIR
Lori Leslie, MD
Associate Professor of Medicine
Hackensack Meridian Health School of Medicine
Director of CLL and Indolent Lymphoma
John Theurer Cancer Center
Hackensack, NJ
PROGRAM OVERVIEW
In this activity we will discuss the relevance of specific genetic and molecular markers in Chronic Lymphocytic Leukemia (CLL), review the current evidence concerning the application of minimal residual disease (MRD) monitoring, and emerging strategies and combinations for CLL management in first-line and relapsed/refractory settings. Finally, we will examine the potential adverse events associated with CLL therapeutics, including specific considerations with combination therapies.
TARGET AUDIENCE
This educational activity is intended for community hematologists, oncologists, and clinicians involved in the assessment, monitoring, and treatment of CLL for patients within the Department of Veteran Affairs.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Evaluate the relevance of specific genetic and molecular markers in CLL for patients within the Department of Veterans Affairs
- Summarize current evidence concerning the application of MRD monitoring in CLL for patients within the Department of Veterans Affairs
- Assess current and emerging strategies and combinations for CLL management in first-line and relapsed/refractory settings for patients within the Department of Veterans Affairs
- Explain potential adverse events associated with CLL therapeutics and considerations with specific combinations for patients within the Department of Veterans Affairs
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure of Relevant Financial Relationships
| Speaker | Relationships | Manufacturer |
| Lori A Leslie, MD | Consultant | ADC Therapeutics, Kite Gilead, BeiGene, Pharmacyclics Inc, Merck Pharmacy, Abbvie, Genmab, SeaGen, Janssen, AstraZeneca, and Eli Lily |
| Speakers Bureau | Kite Gilead, Pharmacyclics, Abbvie, Genmab, SeaGen, Janssen, Eli Lily, Epizyme, TG Therapeutics, BeiGene, and AstraZeneca |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Sylvia Hanna, Medical Services for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Emmanuella Foucault, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITY ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to the enduring activity at info@medlearninggroup.com
RELEASED DATE: August 31, 2023
EXPIRATION DATE: August 31, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Addressing Triple-Class Refractory Veterans Affairs Patients: Treatment with Novel Mechanisms of Action – R/R Multiple Myeloma
PROGRAM CHAIR & FACULTY PRESENTER
Ken H. Young, MD, PhD
Professor and Division Director
Duke University Medical Center
Duke Cancer Center
Durham, NC
PROGRAM OVERVIEW
This enduring program focuses on relapsed/refractory multiple myeloma (R/RMM) and aims to help VA health care professionals recognize overexpressed antigens that can serve as immunologic targets on malignant multiple myeloma plasma cells and how bispecific antibodies can be leveraged as targeted therapy in R/RMM.
TARGET AUDIENCE
This activity is designed to meet the educational needs of Veterans Affairs oncologists, hematologists, hematology pharmacists, nurse practitioners, and physician’s assistants to ensure knowledge and confidence in the management of relapsed/refractory multiple myeloma.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the overexpressed antigens that are bispecific targets on malignant multiple myeloma plasma cells
- Review the pharmacodynamics of bispecific molecules in the relapsed/refractory setting of multiple myeloma
- Evaluate bispecific antibody clinical trial findings for newly approved BCMA-targeted therapy in the treatment of relapsed/refractory multiple myeloma
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Relationships |
| Ken H. Young, MD, PhD | Dr. Young has nothing to disclose. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP Med/Sci Services & Learner Engagement for Med Learning Group, has nothing to disclose.
- Payal Patel, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Laura Aibara, Program Coordinator, for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITY ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to the enduring activity at info@medlearninggroup.com
RELEASED DATE: September 25, 2023
EXPIRATION DATE: September 25, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Grand Rounds
Booth
Summit Meetings
TeleECHOs
